Document:

<PAGE>

                                                                    EXHIBIT 10.9

                         DISTRIBUTION SERVICES AGREEMENT

            THIS DISTRIBUTION SERVICES AGREEMENT is made and entered into this
_____ day of May, 2002, by and between Apheresis Technologies, Inc., a Florida
corporation located at 612 Florida Avenue, Palm Harbor Florida (the "Provider"),
and OccuLogix Corporation, a Florida corporation ("OccuLogix").

                                   WITNESSETH:

            WHEREAS, the Provider is a provider of customer service,
warehousing, order fulfillment, billing and shipping services; and

            WHEREAS, OccuLogix is initiating marketing into Canada and Mexico
and is in the process of obtaining FDA approval for the sale and distribution of
its Rheopheresis product group, including certain disposable filters, tubing and
pump machines (the "Product'); and

            WHEREAS, OccuLogix desires to obtain from the Provider certain
services; and

            WHEREAS, the Provider desires to provide certain services to
OccuLogix.

            NOW, THEREFORE, in consideration of the mutual obligations and
promises set forth herein, the Provider and OccuLogix agree as follows:

1.    Term. The term of this Agreement shall commence on the date hereof and
      shall continue until the date ten years subsequent to the "Approval Date."
      For purposes of this Agreement, the term "Approval Date" shall mean the
      date on which the FDA grants to OccuLogix PMA approval to sell the Product
      in the US; provided, however, that if the Approval Date shall not have
      occurred by May 1, 2012, this Agreement shall terminate.

2.    Services. The parties agree that the Provider shall be the exclusive
      provider to OccuLogix of warehousing, order fulfillment, shipping, billing
      services and customer service related to shipping and billing all as
      further provided herein.

3.    Warehousing. OccuLogix, at its expense, shall ship a quantity of Product
      inventory determined by OccuLogix to the premises of the Provider at 612
      Florida Avenue, Palm Harbor Florida, or other such facility as deemed
      necessary or appropriate by the Provider. The Provider shall store,
      maintain, manage and account for such inventory in accordance with
      warehouse procedures to be agreed upon from time to time by the parties,
      but will at a minimum materially satisfy all FDA and or other regulatory
      requirements as may be necessary. As such, the Provider agrees to remain
      in compliance with all pertinent regulations at all times.

4.    Order Fulfillment; Customer Service. Orders for the Product, whether
      received by OccuLogix or directly by the Provider, shall be forwarded to
      the Provider for processing. Upon Provider's receipt of confirmation of
      the purchase from OccuLogix, the order shall be picked from inventory on a
      FIFO basis, packed, labeled and otherwise prepared for

<PAGE>

                                      -2-

      shipping by the Provider, all in accordance with order fulfillment
      procedures to be agreed upon from time to time by the parties.

5.    Shipping; Billing. The Provider agrees to ship all orders processed
      hereunder in accordance with shipping procedures to be agreed upon from
      time to time by the parties. At the time of shipment, the Provider shall
      invoice the customer in accordance with procedures approved by OccuLogix
      and shall enter such invoice information into a billing and collection
      system specified by OccuLogix.

6.    Reporting. The Provider shall report its activities hereunder to OccuLogix
      in reasonable detail on a daily basis using such report formats as are
      agreed upon from time to time by the parties.

7.    Fees. OccuLogix shall pay to the Provider service fees for the services
      provided hereunder in accordance with the following terms:

            (a)   OccuLogix shall pay to the Provider a basic service fee of 5%
                  of the cost of delivered goods. For purposes of this
                  Agreement, the tern "cost of delivered goods" shall mean the
                  purchase price paid by OccuLogix for the goods, together with
                  all shipping and related charges to the Provider's warehouse.
                  For the purposes of this agreement, the basic service fee
                  shall be compensation for all preparation and handling of
                  shipments, customer service of shipping, handling and returns,
                  all invoicing activities and warehousing (including labor
                  costs for employees directly involved in the performance of
                  such services).

            (b)   In addition, Occulogix shall pay the Provider the cost of
                  shipping between Provider and customer including any required
                  packaging and labeling (materials and labor).

            (c)   The Provider shall invoice OccuLogix for services monthly.
                  Invoices are due 30 days after the date of the invoice. The
                  invoice shall be in a format with sufficient detail for use by
                  OccuLogix for financial reporting and management planning
                  purposes.

8.    Examination of Records. Upon not less than 48 hours notice, each party
      shall be entitled to examine the records of the other party regarding the
      performance of the parties under this Agreement on regular business days
      (Monday through Friday) and during regular business hours (8:30 A.M. -
      5:00 P.M. Eastern Time).

9.    Notices. Notice by either party will be made only in writing by certified
      mail, return receipt requested or facsimile addressed to the other party
      and will be considered given as of the time it is received. Addresses for
      notices are as follows:

                                               Provider:
                                               Apheresis Technologies, Inc

<PAGE>

                                      -3-

                                               612 Florida Avenue
                                               Palm Harbor FL 34683
                                               FAX: 784-0898

                                               OccuLogix Corporation
                                               612 Florida Avenue
                                               Palm Harbor FL 34683
                                               FAX: 784-0898

            Changes to the notice addresses may be accomplished by notice in
accordance with this paragraph.

10.   Risk of Loss and Insurance.

            (a)   The risk of loss of OccuLogix inventory shall at all times be
                  borne by OccuLogix; provided, however, that any damage
                  occurring as a result of negligence of the Provider shall be
                  the responsibility of the Provider.

            (b)   Each party shall be responsible for maintaining insurance upon
                  its own inventory, equipment, furniture, fixtures, supplies
                  and other property located upon the premises of the Provider.

            (c)   Each party shall carry General Liability Insurance in the
                  amount of not less than $1,000,000 per occurrence/$2,000,000
                  aggregate during the term of this agreement.

            (d)   Each party shall furnish evidence to the other party of its
                  compliance with this paragraph.

11.   Confidential Information. The parties hereto consider this Agreement and
      all of its terms and conditions to be confidential. Except as may have
      been, or shall be, authorized in writing, or as hereinafter mentioned,
      each of the parties hereto shall keep confidential and shall not use
      otherwise than in the performance of this Agreement and shall take all
      reasonable steps to insure that its employees keep confidential and not
      use, all information supplied to them or which they have learned during
      the negotiations leading to this Agreement or learned hereafter concerning
      the business of the other. This obligation shall survive the termination
      of this Agreement and for 5 years after any termination of this Agreement.
      Nothing herein shall preclude disclosure of information to the extent that
      the disclosure is required to be made under laws or regulations in force
      and applicable to the party, or pursuant to a subpoena; provided, however,
      the party required to disclose any such confidential information shall
      immediately, upon receipt of a subpoena, notice, demand or order to
      produce the information, and prior to complying with the subpoena, notice,
      demand, or order, notify the other party of said subpoena, notice, demand
      or order and at the request of the other party, contest or join with the
      other party in contesting the propriety and/or authority of disclosing the
      information. Each party shall bear its own costs of complying with the
      provisions of this paragraph.

<PAGE>

                                      -4-

12.   Independent Contractor. The parties each agree and acknowledge that this
      Agreement does not constitute a joint venture or partnership. This
      Agreement has been reached by arms' length negotiations and is an
      independent services contract in which the Provider acts as an independent
      contractor.

13.   Assignability. This Agreement and the rights and obligations hereunder may
      not be assigned by either party without the prior written consent of the
      other party.

14.   Force Majeure. Except for the payment of money due hereunder, the Provider
      and OccuLogix shall be excused for failure to perform under this Agreement
      where such failure results from circumstances beyond the affected party's
      control including, without limitation, such circumstances as fire, storm,
      flood, earthquake, strikes, work stoppages or slow downs, delay or failure
      of transportation or supplies, acts of the public enemy, acts of God or
      acts, regulations, priorities or actions of the United States, a state or
      any local government or agents or instrumentalities thereof.

15.   Governing Law. This Agreement shall be interpreted, and the rights,
      obligations and liabilities of the parties determined in accordance with
      the laws of the State of Florida (without regard to the conflicts of laws
      provisions thereof). The parties agree that any litigation arising out of
      this Agreement or performance of it by either party shall be litigated in
      either the Circuit Court of Pinellas County, Florida, or the United States
      District Court for the Middle District of Florida, Tampa Division.

16.   Amendments. No alteration, modification or change of this Agreement shall
      be valid except by an agreement in writing executed by both parties
      hereto.

17.   Dispute Resolution. The Provider and OccuLogix will attempt to settle any
      claim or controversy arising out of this Agreement through consultation
      and negotiation in good faith and a spirit of mutual cooperation. If those
      attempts fail, then the dispute will be mediated by a mutually acceptable
      mediator to be chosen by the Provider and OccuLogix within 45 days after
      written notice by either to the other demanding mediation. Neither party
      may unreasonably withhold consent to the selection of a mediator, and the
      Provider and OccuLogix will share the cost of the mediation equally. By
      mutual agreement, the Provider and OccuLogix may postpone mediation until
      some specified but limited discovery about the dispute has been completed.
      The parties may also agree to replace mediation with some other form of
      alternative dispute resolution. Any dispute which cannot be resolved
      between the parties through negotiation, mediation or other form of agreed
      alternative dispute resolution within 120 days of the date of the initial
      demand for it by one of the parties may then be submitted to the courts
      for resolution. Nothing in this section will prevent either party from
      resorting to judicial proceedings if (A) good faith efforts to resolve the
      dispute under these procedures have been unsuccessful, (B) interim relief
      from a court is necessary to prevent serious and irreparable injury to one
      party or to others, or (C) litigation is required to be filed prior to the
      running of the applicable statute of limitations. The use of any
      alternative dispute resolution procedure will not be construed under the
      doctrines of laches, waiver or estoppel to affect adversely the rights of
      either party.

<PAGE>

                                      -5-

18.   Severability. In the event that any provision or any portion of any
      provision of this agreement is held illegal, unenforceable, or invalid by
      any Court, such provision or portion thereof shall be deemed to be deleted
      from this agreement, and the validity of the remainder of this agreement
      shall remain unaffected thereby.

19.   Entire Agreement. This Agreement constitutes the entire Agreement and
      understanding of the parties with regard to the matters covered herein.

20.   Attorneys' Fees. If any suit, action or arbitration is initiated by any
      party to enforce this Agreement or otherwise with respect to the subject
      matter of this Agreement, the prevailing party in such suit, action or
      arbitration shall be entitled to recover reasonable attorneys' fees and
      expenses, including but not limited to travel, incurred in the preparation
      and prosecution or defense of such suit, action or arbitration, and if any
      appeal is taken from the decision of the trial court or arbitrator,
      reasonable attorneys' fees for such appeal.

21.   Events of Default. The occurrence of one or more of the following events
      (an "Event of Default") shall constitute a default hereunder:

            (a)   Covenants. The failure of either party hereto to perform or
                  observe any covenant, term or condition binding on it
                  contained herein if such default is not remedied within 30
                  days after written notice thereof from the non-defaulting
                  party.

            (b)   Liquidation; Bankruptcy. In the case of the Provider, the
                  liquidation or dissolution of the Provider, or the filing by
                  or against the Provider of a petition seeking relief under the
                  United States Bankruptcy Code, as amended, or under any other
                  insolvency act or law.

            (c)   Business Suspension. In the case of the Provider, the
                  suspension of the Provider's business by a governmental agency
                  or instrumentality, including without limitation the United
                  States Food and Drug Administration, as a result of any
                  alleged violation by the Provider of any law, rule or
                  regulation administered or promulgated by such agency or
                  instrumentality.

22.   Remedies. Upon the occurrence of any Event of Default, and at any time
      thereafter as long as the Event of Default is continuing, the
      nondefaulting party may terminate this Agreement and may pursue all
      rights, remedies or recourses available to such party at law, in equity or
      otherwise. Such remedies are cumulative, and exercisable concurrently, and
      may be pursued singularly, successively or together and may be exercised
      as often as occasion therefore shall arise.

<PAGE>

                                      -6-

            IN WITNESS WHEREOF, each of the parties hereto have caused this
Agreement to be signed by its respective duly authorized representative.

                                               Apheresis Technologies, Inc.

                                               By: /s/ John Cornish
                                                   ___________________________

                                               OccuLogix Corporation

                                               By: /s/ Richard Davis
                                                   ___________________________<PAGE>

                                                                   EXHIBIT 10.10

                              CONSULTING AGREEMENT

            THIS AGREEMENT (the "Agreement") is made by and between OccuLogix
Corporation, a Florida Corporation (the "OccuLogix"), and Dipl. Ing. Hans K.
Stock, an individual living in Germany ("Stock").

            WHEREAS, Stock seeks to assist OccuLogix in procuring a license (the
"License") to US patent 6,245,038 issued June 12, 2001 (the "Patent") from Prof.
Dr. Helmut Borberg and or Prof. Dr. Richard Brunner, both individuals living in
Germany and both listed as inventors in provisional US patent application
60/034,909 (the "Inventors") which is the parent and domestic-priority
application of US letters patent 6,245,038 issued June 12, 2001, and

            WHEREAS, OccuLogix desires to acquire the License to the Patent and
requests Stock's assistance in procuring said License.

            NOW THEREFORE, in consideration for the Retainer and Consulting
Payments as described below, and other good and valuable consideration, the
Parties enter into this Consulting Agreement in accordance with the terms set
forth below.

1.    Representation by Stock. Stock warrants that he is a natural person living
      in Germany who, along with Prof. Dr. Richard Brunner and Prof. Dr. Helmut
      Borberg, is listed as an inventor in provisional US patent application
      60/034,909 which is the parent and domestic-priority application of US
      letters patent 6,245,038 issued June 12, 2001.

2.    Representation by OccuLogix. OccuLogix represents that it is a bona fide
      corporation in good standing in Florida.

3.    Patent Rights. Shall mean any and all of the rights, title, ownership and
      interests in and to US letters patent 6,245,038 and any and all
      inventions, modifications, continuations-in-part, extensions, divisions,
      improvements, etc., in any and all areas that relate directly to the
      Patent, regardless of whether such inventions or improvements are
      patentable or may become patented; It is expressly agreed that any and all
      such inventions, modifications, continuations-in-part, extensions,
      divisions, improvements, etc. shall automatically be incorporated herein
      without the payment of any additional fees, royalties or any other
      compensation or considerations of any kind.

4.    Consulting Retainer Payments. OccuLogix agrees to pay Stock Fifty Thousand
      Dollars ($50,000 USD) annually as an advance and credited against any and
      all Consulting Payments paid in accordance with this License. Such
      Consulting Retainer Payments shall be paid to Stock in equal payments of
      Twelve Thousand Five-hundred Dollars ($12,500 USD), made quarterly, on or
      before the expiration of Forty-five (45) days after the reporting close of
      each prior calendar quarter. The initial payment of Twelve Thousand
      Five-hundred Dollars ($12,500 USD) shall be due and payable within
      Forty-five (45) Days of the Effective Date herein.

<PAGE>

                                      -2-

5.    Consulting Payments. OccuLogix agrees to pay Stock a total of One Percent
      (1.0% USD) of Total Net Revenues that OccuLogix receives from the bona
      fide commercial sales of its Products sold in reliance and dependence upon
      the validity of the Patent's claims and of the Patent Rights in the
      Territory. All payments due hereunder shall continue until the termination
      of the Agreement, to Stock, his assigns, heirs, or otherwise; even in the
      event of Stock's death.

6.    Accounting and Timing of Royalty Payments. Upon making each Royalty
      Payment, Licensee shall provide Stock with a summary of the accounting
      used to determine the amount of Royalty Payment due. Royalty Payments
      shall be made by wire transfer and shall be computed on Total Net Revenues
      received by the Licensee by the reporting close of each calendar quarter
      and distributed and paid to Stock and on a quarterly basis, on or before
      the expiration of Forty-five (45) days after the reporting close of each
      prior calendar quarter.

7.    Territory. Shall mean the United States and any other jurisdictions
      subject to recognizing any valid claims of the Patent or of the Patent
      Rights.

8.    Total Net Revenues. shall mean total gross revenues less any discounts,
      rebates, shipping costs, handling costs, transportation insurance costs,
      importation fees, and duties on any and all Products sold by the Licensee
      in the Territory and which are sold in reliance upon and specifically used
      in accordance with or subject to any of the valid claims of the Patent.

9.    Records. OccuLogix agrees to keep complete and correct books, accounts and
      records according to Generally Accepted Accounting Principles (GAAP)
      regulations to facilitate computation of Royalty Payments. Stock, or his
      representatives acceptable to OccuLogix, shall have a full right of
      accounting including the right to confidentially examine OccuLogix's books
      and records, at all reasonable times and upon reasonable notice, for the
      purpose of verifying the amount of Royalty Payments due.

10.   Products. Shall mean any of the Licensee's products, goods or technologies
      sold to unaffiliated third parties in the Territory for the purposes of
      providing extracorporeal therapies for the treatment of the ophthalmic
      diseases as defined by any valid claim(s) of the Patent. In this case,
      Licensee's sale of extracorporeal filters and tubing sets for use in any
      and all ophthalmic indications.

11.   Term. The Royalty Payments shall be due to Stock beginning with the first
      bona fide commercial sale of any Product in the Territory and shall
      terminate upon the first of any of the following three events to occur: a)
      All patents of the Patent Rights expire, b) All patent claims of the
      Patent Rights are invalidated, or c) A similarly fashioned competitive
      extracorporeal product, method or technology is commercially introduced in
      the Territory for use in ophthalmic indications that could not be deterred
      by best-efforts enforcement/infringement proceedings brought by Licensee
      against the competitive product, method or technology where such
      proceedings are made in reliance in full or in part upon the Patent's
      claims and or the Patent Rights.

<PAGE>

                                      -3-

12.   Relationship of the Parties; Indemnification. It is agreed that this
      Agreement does not make either Party herein a general or special agent,
      legal representative, subsidiary, joint venturer, partner, employee or
      servant of the other Party herein for any purpose.

13.   Breach and Disputes. Any breaching Party shall have Thirty (30) Days from
      the date of notification to cure such breach. Any dispute between the
      Parties to this Agreement shall be resolved through binding arbitration,
      which shall be governed under the rules and regulations of the American
      Arbitration Association.

14.   Forum, Venue and Governing Law. This Agreement shall be governed and
      interpreted under Delaware law (without applying its conflict of law
      principles). Exclusive venue for legal proceedings arising hereunder shall
      be in Hillsborough County, Florida.

15.   Entire Agreement. This Agreement supersedes any prior understanding that
      may have been reached between the Parties and encompasses the entire
      agreement between the Parties with respect to the Patent and the Patent
      Rights. The terms of this Agreement are confidential and shall be
      maintained by the Parties in accordance thereby.

16.   Modification. This Agreement cannot be modified except in writing executed
      mutually between the Parties.

            IN WITNESS WHEREOF, the Parties have signed and executed this
Agreement and have caused this Agreement to become effective as of the Effective
Date last executed below.

OCCULOGIX CORPORATION                          DIPL. ING. HANS K. STOCK

By:        Richard Davis                               /s/ Hans Stock
    ___________________________                _________________________________

Title:    President and CEO
       ________________________

Date:       June 25, 2002                      Date:       June 25, 2002
      _________________________                       __________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}]]